Commentary

iMedPub Journals
www.imedpub.com

Journal of HIV & Retrovirus
ISSN 2471-9676

2021
Vol.7 No.2:1

The Evolution of HIV Vaccine

Mateo Arola*

IrsiCaixa AIDS Research Institute, Badalona, Spain

Corresponding author: Mateo Arola, IrsiCaixa AIDS Research Institute, Badalona, Spain, E-mail: mateo_a@irsicaixa.es

Received date: August 30, 2021; **Accepted date:** September 13, 2021 **; Published date:** September 20, 2021

Citation: Arola M (2021) The Evolution of HIV Vaccine. J HIV Retrovirus Vol.7 No.2: 1.

Description

The Human Immunodeficiency Virus vaccine can either be used as a prophylactic vaccine or as a curative in which prophylactic reaction helps to safeguard a person from being infected with an HIV vaccine and cures for the person who got infected with HIV respectively. It can either generate an immunologic reaction against HIV or inclusion of intended antibodies against HIV which means an active immunization method and a passive immunization method respectively.

Nowadays, there is no certified HIV vaccine that is currently available in the drug stores, but many research projects are investigating to obtain a potent vaccine. Empirical evidence from individuals indicates that a vaccine may be potential. Some individuals with HIV-infected may, of course, generate neutralizing antibodies in general, which maintain the virus suppressed, and these individuals last asymptomatic for ten years. In general, neutralizing antibodies have been replicated in the experiment laboratory (monoclonal antibodies), and take part in the assessment of passive vaccination clinical trials.

Numerous assessments have exhibited impotence, but single HIV vaccine administration, RV 144 meant the Thai trial, possessed an inhibitory action of HIV in a few cases of Thailand.

The necessity of the research for a vaccine in case of HIV comes from the AIDS-associated mortality toll of around 35 million people since 1981. During the year 2002, AIDS came to be the primary cause of mortality owing to an infectious agent in Africa.

There are different therapies available to manage the vaccine for HIV. Especially for the treatment of HIV-infected persons, Highly Active Antiretroviral Therapy (HAART) medication has shown to produce numerous advantages, such as better well-being, extensive lifespan, management of viremia, and prophylactic treatment in case of transmission to infants and companions. HAART should be administered long-term continuously for the effective result but it cannot be cured. Another alternative treatment of HIV infection in HIV-uninfected persons involves the use of protected sex, and antiretrovirals such as pre-exposure prophylaxis and post-exposure prophylaxis. Vaccination has shown a potent community health device to overcome additional diseases, and the HIV vaccine is broadly taken into consideration as the uttermost possible way by which the HIV pandemic can be terminated. Anyhow, HIV lasts a challenging aim for a vaccine.

The classic animal model for vaccine testing is the monkey. Monkeys can be infected with Simian Immunodeficiency Virus (SIV) or the chimeric Simian Human Immunodeficiency Virus (SHIV) in case of study reasons. Although, the well-demonstrated direction of testing to cause neutralizing antibodies by vaccination has inhibited the serious trouble in activating antibodies that neutralize heterologous primary HIV isolates. A few vaccines exhibit that the virus envelope has safeguarded chimpanzees' out-of homologous virus challenge, yet in clinical trials, humans who were vaccinated with similar formulations of vaccine got affected further in the later exposure to HIV-1.

There are a few differences between SIV and HIV that may bring challenges in the use of an animal model. The animal model can significantly be useful yet sometimes disagreeable which may sometimes be problematic.

There is a new animal model that greatly mimics HIV in humans. Universal immune stimulation as the shortest effect of activated CD4+ T cell killing – carried out in mice permits advanced methods of analysing HIV behavior.

NIAID-funded SIV research has shown that challenging monkeys with a cytomegalovirus (CMV)-based SIV vaccine results in the retention of the virus. In general, virus replication and spreading occur within days after the contamination, whereas vaccine-induced T cell activation and recruitment to sites of viral replication take weeks. Researchers postulated that vaccines designed to maintain activated effector memory T cells which might impair viral replication at its earliest stage.